relatlimab

{{Infobox drug

| type = mab

| image =

| width =

| alt =

| caption =

| mab_type = mab

| source = u

| target = Lymphocyte activation gene-3 (LAG-3)

| tradename =

| Drugs.com =

| MedlinePlus =

| DailyMedID = Relatlimab

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = Intravenous

| class = Antineoplastic

| ATCvet =

| ATC_prefix = None

| ATC_suffix =

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA = Rx-only

| legal_CA_comment = {{cite web | title=Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22] | website=Health Canada | date=22 December 2023 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2023-12-22.html | access-date=3 January 2024}}

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = only in combination with nivolumab

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1673516-98-7

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank = DB14851

| ChemSpiderID =

| UNII = AF75XOF6W3

| KEGG = D11350

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = BMS-986016, relatlimab-rmbw

| IUPAC_name =

| C = 6472 | H = 9922 | N = 1710 | O = 2024 | S = 38

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Relatlimab is a monoclonal antibody designed for the treatment of melanoma.{{cite book | veditors = Cavagnaro JA, Cosenza ME |title=Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals |date=2021 |publisher=CRC Press | location = Boca Raton, Florida |isbn=978-1-00-047185-4}}{{cite journal | vauthors = Robert C | title = LAG-3 and PD-1 blockade raises the bar for melanoma. | journal = Nature Cancer | date = December 2021 | volume = 2 | issue = 12 | pages = 1251–3 | doi = 10.1038/s43018-021-00276-8 | pmid = 35121906 | s2cid = 245407697 }} It is used in combination with nivolumab to treat melanoma.

Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.{{cite web | title=Opdualag- nivolumab and relatlimab-rmbw injection | website=DailyMed | date=18 March 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b22c9d83-3256-4e17-85f7-f331a504adc6 | access-date=22 March 2022}} It is under development by Bristol-Myers Squibb. It is made using Chinese hamster ovary cells.

History

{{as of|2018}}, relatlimab is undergoing Phase II/III trials.{{ClinicalTrialsGov|NCT03704077|An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma}}

The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.{{cite press release | title=U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma | publisher=Bristol Myers Squibb | via=Business Wire | date=18 March 2022 | url=https://www.businesswire.com/news/home/20220304005561/en/U.S.-Food-and-Drug-Administration-Approves-First-LAG-3-Blocking-Antibody-Combination-Opdualag%E2%84%A2-nivolumab-and-relatlimab-rmbw-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma | access-date=19 March 2022}}

Names

Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).{{cite web | title=Relatlimab | website=American Medical Association | url=https://searchusan.ama-assn.org/finder/usan/search/RELATLIMAB/relevant/1/ | access-date=22 March 2022}}[http://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Frelatlimab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab], American Medical Association.{{cite journal | vauthors=((World Health Organization)) | year=2019 | title=International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81 | journal=WHO Drug Information | volume=33 | issue=1 | page= | hdl=10665/330896 | hdl-access=free | author-link = World Health Organization }}

References

Category:Drugs developed by Bristol Myers Squibb

Category:Experimental monoclonal antibodies

Category:Monoclonal antibodies for tumors